Scorpius And Celltheon Team Up For Cell Line Development And Biomanufacturing

Scorpius Holdings, Inc. is a contract development and management organisation (CDMO) that recently partnered with Celltheon Corporation, offering cell line development services using Celltheon's exclusive GOLDILOCKS™ transposase-based platform. The alliance allows clients to collaborate closely with Scorpius' project management and quality assurance teams to transfer research cell bank (RCB) to the company's San Antonio, TX facility for further biomanufacturing processes. 

Through this partnership, Scorpius customers will have comprehensive cell line development and other services by Celltheon, such as antibody discovery, variant screening, development, and comparability studies. The first customer under this agreement is already preparing for GMP manufacturing scale-up with Scorpius.

“We are excited to collaborate with Celltheon, a partner that shares Scorpius’ mission to deliver responsive, high-quality, flexible services to early-stage biotechs and academic researchers. This partnership allows our clients to secure their supply chain and intellectual property by working with Celltheon, a California-based company, and then transferring their high-expressing, stable cell line to our state-of-the-art GMP facility in Texas to continue manufacturing,” said Jeff Wolf, CEO of Scorpius.

Divya Goel, VP of Business Development and Board Member at Celltheon, also stated, “We look forward to helping Scorpius clients overcome their early development challenges so they can seamlessly move to GMP activity. Together, Celltheon and Scorpius are committed to ensuring that the next generation of biotherapeutics gets to patients faster and more affordably.”